12:01 PM EST - Novoheart Holdings Inc. : A global stem cell biotech company that invented and commercialized the world’s first and only "human heart-in-a-jar" model for drug discovery and development, is pleased to announce an exclusive licensing agreement with Harvard University’s Office of Technology Development. Novoheart Holdings Inc.
shares V.NVH are trading up $0.04 at $0.58.
